{"id":3825,"date":"2019-05-29T05:40:20","date_gmt":"2019-05-29T05:40:20","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/nanexas-samarbete-gar-in-i-ny-fas\/"},"modified":"2019-05-29T05:40:20","modified_gmt":"2019-05-29T05:40:20","slug":"nanexas-samarbete-gar-in-i-ny-fas","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexas-samarbete-gar-in-i-ny-fas\/","title":{"rendered":"Nanexas samarbete g\u00e5r in i ny fas"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><span><strong><\/strong><\/span><\/p>\n<\/div>\n<p><span>Det Svenska l\u00e4kemedelsbolaget som startade utv\u00e4rdering av Nanexas drug delivery plattform PharmaShell har nu beslutat att g\u00e5 vidare och ut\u00f6ka utv\u00e4rderingen av PharmaShell\u00ae\u00a0som drug deliveryplattform f\u00f6r ett av deras produktprojekt.<\/span><\/p>\n<p><span>Utv\u00e4rderingen som startade i januari har gett lovande resultat och arbetet i den nya fasen g\u00e5r nu in mot att styra fris\u00e4ttningen mot en specifik m\u00e5lbild f\u00f6r den t\u00e4nkta produkten. \u00c4ven denna fas inkluderar en in-vitro utv\u00e4rdering som planeras f\u00f6ljas upp av ytterligare en in-vivo studie.<\/span><\/p>\n<p><span>I det nu \u00f6verenskomna samarbetet som regleras av samma\u00a0\u201dMaterial Transfer and Feasibility study agreement\u201d\u00a0som signerades den 17\/12, 2018 erh\u00e5ller Nanexa \u00f6verenskomna mindre betalningar vid leverans av\u00a0in vitro-resultat samt vid leverans av material till en\u00a0in vivo-studie. Det svenska l\u00e4kemedelsbolaget som Nanexa tecknat avtal med bekostar \u00e4ven den\u00a0in vivo-studie\u00a0som planeras inom ramen f\u00f6r utv\u00e4rderingen.<\/span><\/p>\n<p><span>Nanexas VD David Westberg kommenterar:<\/span><\/p>\n<p><span>Samarbetet och utv\u00e4rderingen av PharmaShell\u00ae\u00a0har g\u00e5tt helt enligt planerna. Det \u00e4r d\u00e4rf\u00f6r gl\u00e4djande att v\u00e5r samarbetspartner vill g\u00e5 vidare med ett mer specifikt uppdrag som tar oss n\u00e4rmare en m\u00f6jlig produktkandidat och ett potentiellt l\u00e5ngsiktigt samarbete.<\/span><\/p>\n<p><span>F\u00f6r mer information kontakta:<br \/>David Westberg\u00a0\u2013\u00a0VD, Nanexa AB (publ)\u00a0Telefon: 0709-42 83 03<br \/>E-post: david.westberg@nanexa.se www.nanexa.com<\/span><\/p>\n<p><span>Denna information \u00e4r s\u00e5dan information som Nanexa AB \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 29 maj, 2019.<\/span><\/p>\n<p><span>Om Nanexa AB (publ)<br \/>Nanexa AB \u00e4r ett nanoteknologiskt drug deliveryf\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen av PharmaShell\u00ae\u00a0som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae\u00a0har Nanexa samarbetsavtal med bland andra AstraZeneca.<\/span><\/p>\n<p><\/p>\n<p><span><strong><\/strong><\/span><\/p>\n<p><\/p>\n<p><span><strong><\/strong><\/span><\/p>\n<div class=\"mfn-footer mfn-attachment\">\n<p><strong>Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a href=\"https:\/\/mb.cision.com\/Main\/12591\/2827880\/1053693.pdf\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Read as PDF<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<\/p>\n<p>Det Svenska l\u00e4kemedelsbolaget som startade utv\u00e4rdering av Nanexas drug delivery plattform PharmaShell har nu beslutat att g\u00e5 vidare och ut\u00f6ka utv\u00e4rderingen av PharmaShell\u00ae\u00a0som drug deliveryplattform f\u00f6r ett av deras produktprojekt.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexas-samarbete-gar-in-i-ny-fas\/\">L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-3825","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexas samarbete g\u00e5r in i ny fas - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexas-samarbete-gar-in-i-ny-fas\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexas samarbete g\u00e5r in i ny fas - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Det Svenska l\u00e4kemedelsbolaget som startade utv\u00e4rdering av Nanexas drug delivery plattform PharmaShell har nu beslutat att g\u00e5 vidare och ut\u00f6ka utv\u00e4rderingen av PharmaShell\u00ae\u00a0som drug deliveryplattform f\u00f6r ett av deras produktprojekt.L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexas-samarbete-gar-in-i-ny-fas\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-samarbete-gar-in-i-ny-fas\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-samarbete-gar-in-i-ny-fas\\\/\",\"name\":\"Nanexas samarbete g\u00e5r in i ny fas - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2019-05-29T05:40:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-samarbete-gar-in-i-ny-fas\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-samarbete-gar-in-i-ny-fas\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-samarbete-gar-in-i-ny-fas\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexas samarbete g\u00e5r in i ny fas\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexas samarbete g\u00e5r in i ny fas - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexas-samarbete-gar-in-i-ny-fas\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexas samarbete g\u00e5r in i ny fas - Nanexa AB","og_description":"Det Svenska l\u00e4kemedelsbolaget som startade utv\u00e4rdering av Nanexas drug delivery plattform PharmaShell har nu beslutat att g\u00e5 vidare och ut\u00f6ka utv\u00e4rderingen av PharmaShell\u00ae\u00a0som drug deliveryplattform f\u00f6r ett av deras produktprojekt.L\u00e4s mer","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexas-samarbete-gar-in-i-ny-fas\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-samarbete-gar-in-i-ny-fas\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexas-samarbete-gar-in-i-ny-fas\/","name":"Nanexas samarbete g\u00e5r in i ny fas - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2019-05-29T05:40:20+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-samarbete-gar-in-i-ny-fas\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexas-samarbete-gar-in-i-ny-fas\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-samarbete-gar-in-i-ny-fas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexas samarbete g\u00e5r in i ny fas"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}